Vertex Pharmaceuticals Incorpor Price Today
Vertex Pharmaceuticals Incorpor
VRTX
Healthcare
$104.47B
💰
Market Cap
29.1
💸
Price to Earnings
$13.9
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
16 |
Strong Buy |
10 |
Hold |
10 |
Sell |
1 |
Strong Sell |
1 |
VRTX Price Forecast Target
404.2 👉 574.0 +42%
VRTX EPS Forecast
13.9 👉 18.4 +32%
Financials
Profit Margin
37 %
Revenue Growth
9.3 %
Dividend
$ 0
Held Percent
0.1% - Insiders
95.7% - Institutions
4.2% - Public
Major Fund Holders
-
💰 $
-
💰 $
-
💰 $
-
💰 $
-
💰 $
Stock Ideas
Charlie Munger Portfolio
Charlie Munger, the renowned investor and Vice Chairman of Berkshire Hathaway, is a true titan in the world of finance. Often referred to as Warren Buffett's right-hand man, Munger's portfolio investment approach is a masterclass in disciplined and …
Louis Bacon Portfolio
Louis Bacon is the founder of Moore Capital Management and is one of the famous traders of the past two decades. His personal wealth is more than $1.5 Billion and had more than $15 Billion in AUM. He has an MBA degree from Columbia Business School.
Bill Gates Portfolio
With a portfolio valued at over $18 billion, the Bill & Melinda Gates Foundation Trust holds the endowment and funds the Bill & Melinda Gates Foundation. Bill and Melinda are the trustees for the Foundation Trust, and the endowment is managed by a t…
Jim Chanos Portfolio
Jim Chanos is a revered figure in the world of portfolio management, known for his expertise in short selling and his pivotal role in uncovering fraud at Enron and WorldCom. Hailing from Milwaukee and a graduate of Yale with an economics degree, Ch…📮FAQ
Some Frequently Asked Questions.
The Vertex Pharmaceuticals Incorpor industry is Biotechnology
The Vertex Pharmaceuticals Incorpor sector is Healthcare
The Vertex Pharmaceuticals Incorpor forecasted predicted Price to Earnings PE ratio is 22.0
The Vertex Pharmaceuticals Incorpor Price to Earnings PE ratio is 29.1
The Market Capitalization of Vertex Pharmaceuticals Incorpor is $104.47B
There are total of 257563889 float shares with 95.7% held by Institutions and 0.1% held by insiders
The MVertex Pharmaceuticals Incorpor forecasted Earnings per Share EPS is $18.4
The Vertex Pharmaceuticals Incorpor Earnings per Share EPS is 13.9
The Vertex Pharmaceuticals Incorpor company has $0 gross profits with 37 profit margins
The Vertex Pharmaceuticals Incorpor Earnings Growth is 0.181% with 0.183% quarterly earnings growth
The Vertex Pharmaceuticals Incorpor Revenue is $9869200384 with 0.093 revenue growth
The price target for Vertex Pharmaceuticals Incorpor stock is $574.0 for the high target and $325.0 for the low target
The consensus analyst recommendations for Vertex Pharmaceuticals Incorpor is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Vertex Pharmaceuticals Incorpor is Buy, with the following breakdown:
- Buy: 16
- Strong Buy: 10
- Hold: 10
- Sell: 1
- Strong Sell: 1
The Beta of Vertex Pharmaceuticals Incorpor is 0.4
The dividend of Vertex Pharmaceuticals Incorpor is $0
The dividend yield of Vertex Pharmaceuticals Incorpor is 0%
The biggest institutional and mutual fund holders of Vertex Pharmaceuticals Incorpor stock are
The Vertex Pharmaceuticals Incorpor ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0